| Tucker Peck Phd | |
|
2258 Santa Clara Ave Ste 5 Alameda CA 94501-4473 | |
| (415) 802-2860 | |
| (844) 227-8699 |
| Full Name | Tucker Peck Phd |
|---|---|
| Speciality | Psychologist |
| Location | 2258 Santa Clara Ave Ste 5, Alameda, California |
| Authorized Official Name and Position | Tucker Peck (CEO) |
| Authorized Official Contact | 5204859411 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Tucker Peck Phd 2103 San Jose Ave Alameda CA 94501-4994 Ph: (520) 485-9411 | Tucker Peck Phd 2258 Santa Clara Ave Ste 5 Alameda CA 94501-4473 Ph: (415) 802-2860 |
| NPI Number | 1841951399 |
|---|---|
| Provider Enumeration Date | 01/06/2022 |
| Last Update Date | 08/18/2023 |
| Certification Date | 08/18/2023 |
| Medicare PECOS PAC ID | 9739573619 |
|---|---|
| Medicare Enrollment ID | O20220221000274 |
News Archive
The Medical Research Council (MRC) is to fund a research proposal from a team at the North East England Stem Cell Institute (NESCI) for a project to find ways of improving the efficiency of therapeutic cloning - a technique which would allow scientists to create patient-specific stem cells and develop regenerative therapies for many debilitating conditions such as diabetes, heart disease and Parkinson's disease.
Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown.
The collaborative research team led by Professor Tadashi ISA, Project Assistant Professor Masaharu KINOSHITA from The National Institute for Physiological Sciences, The National Institutes of Natural Sciences and Fukushima Medical University and Kyoto University, developed "the double viral vector transfection technique" which can deliver genes to a specific neural circuit by combining two new kinds of gene transfer vectors.
Neurocrine Biosciences, Inc. announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.
IGI Laboratories, Inc.. On May 25, 2010, IGI received notice from the NYSE Amex staff indicating that the Company is below certain of the Exchange's continued listing standards due to losses in five of its most recent fiscal years with equity below $6 million, as set forth in Section 1003(a) (iii) of the NYSE Amex Company Guide. The Company was afforded the opportunity to submit a plan of compliance to the exchange and on June 24, 2010 presented its plan to the Exchange.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841951399 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | (* (Not Available)) | Primary |
| Provider Name | Tucker Peck |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1205291440 PECOS PAC ID: 0446544019 Enrollment ID: I20220221000310 |
News Archive
The Medical Research Council (MRC) is to fund a research proposal from a team at the North East England Stem Cell Institute (NESCI) for a project to find ways of improving the efficiency of therapeutic cloning - a technique which would allow scientists to create patient-specific stem cells and develop regenerative therapies for many debilitating conditions such as diabetes, heart disease and Parkinson's disease.
Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown.
The collaborative research team led by Professor Tadashi ISA, Project Assistant Professor Masaharu KINOSHITA from The National Institute for Physiological Sciences, The National Institutes of Natural Sciences and Fukushima Medical University and Kyoto University, developed "the double viral vector transfection technique" which can deliver genes to a specific neural circuit by combining two new kinds of gene transfer vectors.
Neurocrine Biosciences, Inc. announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.
IGI Laboratories, Inc.. On May 25, 2010, IGI received notice from the NYSE Amex staff indicating that the Company is below certain of the Exchange's continued listing standards due to losses in five of its most recent fiscal years with equity below $6 million, as set forth in Section 1003(a) (iii) of the NYSE Amex Company Guide. The Company was afforded the opportunity to submit a plan of compliance to the exchange and on June 24, 2010 presented its plan to the Exchange.
› Verified 1 days ago
News Archive
The Medical Research Council (MRC) is to fund a research proposal from a team at the North East England Stem Cell Institute (NESCI) for a project to find ways of improving the efficiency of therapeutic cloning - a technique which would allow scientists to create patient-specific stem cells and develop regenerative therapies for many debilitating conditions such as diabetes, heart disease and Parkinson's disease.
Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown.
The collaborative research team led by Professor Tadashi ISA, Project Assistant Professor Masaharu KINOSHITA from The National Institute for Physiological Sciences, The National Institutes of Natural Sciences and Fukushima Medical University and Kyoto University, developed "the double viral vector transfection technique" which can deliver genes to a specific neural circuit by combining two new kinds of gene transfer vectors.
Neurocrine Biosciences, Inc. announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.
IGI Laboratories, Inc.. On May 25, 2010, IGI received notice from the NYSE Amex staff indicating that the Company is below certain of the Exchange's continued listing standards due to losses in five of its most recent fiscal years with equity below $6 million, as set forth in Section 1003(a) (iii) of the NYSE Amex Company Guide. The Company was afforded the opportunity to submit a plan of compliance to the exchange and on June 24, 2010 presented its plan to the Exchange.
› Verified 1 days ago
Center For Social Dynamics Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1025 Atlantic Ave, 101, Alameda, CA 94501 Phone: 510-268-8120 | |
Henry T Freeland Med Corp Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 512 Westline Dr, Suite 203, Alameda, CA 94501 Phone: 510-521-4323 Fax: 510-521-5623 | |
Psychtools Psychology Group P.c. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1402 Park St, Suite G, Alameda, CA 94501 Phone: 510-900-5123 | |
A Better Way, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 401 Pacific Ave, Alameda, CA 94501 Phone: 510-433-8600 Fax: 510-485-7173 | |
Alameda Family Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 500 Pacific Ave, Alameda, CA 94501 Phone: 510-748-4024 | |
Athmindset Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1104 Marianas Ln, Alameda, CA 94502 Phone: 510-206-6095 | |
Alameda Family Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 351 Jack London Ave # 401a405a, Alameda, CA 94501 Phone: 510-748-4006 |